# Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

> **NCT01773785** · PHASE2 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 30 (actual)

## Conditions studied

- Biliary Cancer

## Interventions

- **DRUG:** SPI-1620
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01773785
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773785, "Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01773785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*